This test is most useful if any of these apply to you.
You probably touch dozens of phthalate-containing products before lunch. Diethyl phthalate (DEP) hides in fragrance, lotion, shampoo, nail polish, and the coatings on some pills. Your body breaks DEP down within hours and dumps the leftover, monoethyl phthalate (MEP), into your urine.
This is an exposure marker, not a disease test. It does not tell you something is wrong inside your body. It shows how much of this specific chemical is passing through it right now. Population studies have linked higher MEP, often as part of a mixture of phthalates, to fatty liver, altered blood sugar handling, weight in adolescent boys, and reduced egg quality during fertility treatment.
MEP is the main urinary metabolite of diethyl phthalate. When DEP enters your body through skin contact, swallowed pill coatings, or food packaging, your liver converts it to MEP and your kidneys excrete it. Most of a single DEP exposure leaves your body within 24 hours, with a measured elimination half-life of about 2.1 hours after skin or inhalation exposure.
Because MEP is detected in roughly 98% or more of urine samples from the general U.S. adult population, the question is not whether you are exposed. The question is how much, and whether your level is closer to the lower end or the higher end of what is typical.
Personal care products are the dominant source. Fragranced lotions, perfumes, hair products, deodorants, and nail polish frequently contain DEP as a fixative or solvent. Norwegian and U.S. studies show that people who use more of these products have higher urinary MEP, and that frequent hand and hair washing is also associated with higher levels.
Diet is a smaller contributor for MEP than for some other phthalates, though packaged food and processed staples still play a role. A few specific oral medications use DEP in their slow-release or enteric coatings, including some formulations of didanosine, omeprazole, and theophylline. Users of these products have shown markedly higher urinary MEP than the general population.
In a U.S. study of about 3,137 adults, higher urinary phthalate exposure was linked to metabolic dysfunction-associated fatty liver disease (a buildup of fat in the liver tied to insulin resistance, often called MAFLD). MEP contributed about 21% of the total effect when phthalates were analyzed as a mixture, putting it among the more important individual contributors.
What this means for you: if your MEP is high and you have other signs of metabolic strain, such as a fatty liver on imaging or rising liver enzymes, your phthalate exposure is one variable worth taking seriously rather than dismissing as harmless background.
In a separate study of 645 adults, phthalate metabolites including MEP were positively associated with markers of glucose handling, including fasting glucose and insulin resistance. A larger meta-analysis pooling multiple studies found no clear individual link between MEP and a diagnosis of diabetes, in contrast to several other phthalates. The signal for MEP appears to be on metabolic regulation more than on diabetes itself.
Across European children and adolescents in the HBM4EU Aligned Studies, higher urinary MEP was associated with a higher body mass index z-score (a measure of weight relative to peers of the same age and sex) in adolescent males. Mixture models also flagged MEP as one of the predictors of higher BMI in this group. The same association was not as clear in females or younger children.
In 136 women undergoing in vitro fertilization, higher urinary MEP was associated with fewer eggs retrieved and fewer fertilized eggs. The strongest associations in that study were with other phthalates (the DEHP family), but MEP showed its own signal on egg outcomes.
In meta-analyses of pregnancy loss, MEP did not show a statistically significant link to miscarriage risk, unlike several other phthalate metabolites. The fertility signal for MEP appears stronger than the early-pregnancy signal.
In 213 Spanish adults, higher MEP was positively associated with several blood markers of inflammation and metabolic stress, including PAI-1 (a clotting and metabolic regulator), leptin, IL-18, and MCP-1. Phthalate mixtures including MEP were linked to multiple inflammatory cytokines (immune signaling proteins). These are subtle, subclinical shifts, not full-blown inflammatory disease, but they are consistent with the idea that ongoing phthalate exposure nudges the body toward a slightly more inflamed state.
There are no clinical cutpoints for MEP. The numbers below come from population biomonitoring studies and are illustrative orientation, not health targets. Different labs report MEP in different units (nanograms per milliliter, micrograms per liter, or micrograms per gram of creatinine, which adjusts for how concentrated your urine is). Compare your results within the same lab over time for the most meaningful trend.
| Population | What Was Measured | Typical Level |
|---|---|---|
| U.S. general population | Detection rate | Found in 98% or more of urine samples |
| U.S. and Canadian children with chronic kidney disease | Median urinary MEP | 18.4 nanograms per milliliter, with the top 5% above 223 |
| Taiwan, ages 7 to 17 and adults | 95th percentile | Roughly 200 to 260 micrograms per liter |
What this means for you: a single MEP value at the lower end of these distributions suggests modest exposure on the day you collected. A value near the 95th percentile suggests heavy current exposure, most likely from personal care products you used in the previous 24 hours.
A single MEP reading is a snapshot of the past 24 hours, not your steady-state exposure. In a longitudinal study of children with kidney disease, the within-person reliability of low-molecular-weight phthalates including MEP was moderate, with an intraclass correlation coefficient of 0.39 (a statistical measure where 1.0 means perfectly stable readings and 0 means random fluctuation). Researchers studying the same individuals over time consistently note substantial day-to-day variability, which makes sense given the short half-life.
For a useful picture of your exposure, get a baseline, then retest in 3 to 6 months if you change products, packaged-food habits, or medications. After that, retest at least annually. If you collect a baseline that surprises you, retest within a few weeks before drawing conclusions, since one high reading may simply reflect what you used the day before the test.
Treat a high MEP as an exposure question, not a diagnosis. The most actionable next step is an audit of your personal care products. In a 3-day intervention study of 100 adolescent girls, switching to products labeled free of phthalates, parabens, and certain other chemicals lowered urinary MEP by about 27%. That is a fast, real effect from product swaps alone.
If your MEP is consistently high, also consider testing related phthalate metabolites in the same urine sample to see whether you are dealing with one source or many. If you have other findings such as elevated liver enzymes, a fatty liver on imaging, weight gain you cannot explain, or fertility difficulties, mention your phthalate testing to a clinician familiar with environmental medicine. There is no specialist who treats high phthalates directly; the response is exposure reduction, retesting, and addressing any downstream organ findings on their own merits.
MEP is unusually sensitive to what you did in the past day. Several factors can shift a single reading without saying anything meaningful about your usual exposure:
Evidence-backed interventions that affect your MEP level
Monoethylphthalate is best interpreted alongside these tests.